Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring

治疗癫痫新药大麻衍生物销售额翻番,GW Pharma股价飙升11%

2019-08-07 13:00:36 MarketWatch

本文共752个字,阅读需2分钟

GW Pharmaceuticals PLC reported Tuesday afternoon that sales of its cannabis-derived epilepsy drug more than doubled from the previous quarter, sending shares spiking more than 11% higher in after-hours trading. GW Pharmaceuticals GWPH, +0.73% reported second-quarter sales of $68.4 million for Epidiolex, which uses cannabidiol, a compound present in cannabis plants to treat certain forms of epilepsy. Wall Street analysts had forecast Epidiolex sales of $40.9 million, after GW Pharma reported sales of $33.5 million in the first quarter. “We are pleased to report a strong second quarter of sales of Epidiolex in the U.S., reflecting high demand by U.S. patients, increased prescribing by health care providers, and ongoing progress in payer-coverage determinations,” GW Pharma Chief Executive Justin Glover said in a statement. See also: Short sellers are increasing bets that cannabis stocks will fall Since the drug’s launch, the company said more than 12,000 patients have received prescriptions for the medicine and it has been dispensed to 2,500 doctors. Overall, the company reported second-quarter net income of $79.8 million, or 21 cents a share, compared with losses of $84 million, or 25 cents a share, in the year-ago period. The United Kingdom-based company’s net income benefited from a $104.1 million gain on the sale of one of its intangible assets. Revenue rose to $72 million from $3.3 million in the year-ago period. Cannabis Watch: Aurora Cannabis rallies and lifts cannabis stocks after offering revenue guidance Analysts surveyed by FactSet had estimated overall earnings of a penny a share on revenue of $47 million. For the third quarter, analysts model losses of 14 cents a share on sales of $58.1 million. GW Pharmaceuticals shares closed with a 0.7% gain at $152.42, but were trading close to $170 in the extended session. The stock has gained 57% this year, while the S&P 500 index SPX, +1.30% has increased 13.5%. Max A. Cherney is a MarketWatch reporter based in San Francisco.
GWPharmaceuticalsPLC 周二下午报道,其大麻衍生癫痫药物的销售额比上一季度增长了一倍多,导致其股价在盘后交易中飙升逾11%。 GW 制药GWPH ,+0.73%据报道, Epdiolex 公司第二季度销售额为6,840万美元,该公司使用大麻植物中的一种化合物大麻来治疗某些形式的癫痫。华尔街分析师曾预测 Epidelex 销售额为4090万美元,此前 GWPharma 公布第一季度销售额为3350万美元。 GW Pharma 首席执行官贾斯汀•格洛弗( Justin Glover )在一份声明中表示:“我们高兴地报告 Epidelex 在美国的第二季度销售强劲,反映出美国患者的高需求、医疗保健提供者开出的处方增多以及支付者覆盖率决定的持续进展。” 另见:卖空者越来越多地押注大麻股票将下跌 该公司表示,自该药物上市以来,已有1.2万多名患者获得了该药物的处方,并已分发给2500名医生。 总体而言,该公司第二季度净利润为7980万美元,合每股21美分,而去年同期亏损8400万美元,合每股25美分。这家总部位于英国的公司的净收入得益于出售其一项无形资产获得的1.041亿美元收益。收入从去年同期的330万美元增加到7200万美元。 大麻观察:在提供收入指导后,奥罗拉·坎纳比斯(奥罗拉(Aurora) Cannabis )上涨大麻库存 FactSet 调查的分析师估计,公司总收入为4700万美元,每股收益为1美分。 分析师预测,第三季度每股亏损14美分,销售额为5810万美元。 GW Pharmaceuticals 股价收盘上涨0.7%,至152.42美元,但在延续交易时段接近170美元。该股今年上涨了57%,标准普尔500指数上涨 SPX ,+1.30%增长了13.5%。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文